Runben Biotechnology Co., Ltd. (SHA:603193)
China
· Delayed Price · Currency is CNY 34.87
+1.85 (5.60%)
Apr 24, 2025, 2:45 PM CST
Runben Biotechnology Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | 306.18 | 226.03 | 160.04 | 120.65 | 94.71 | 35.67 |
| Depreciation & Amortization | 21.64 | 21.64 | 19.77 | 10.53 | 8.01 | 8.01 |
| Other Amortization | 0.34 | 0.34 | - | - | - | - |
| Loss (Gain) From Sale of Assets | -0.07 | -0.07 | -0.05 | -0 | - | - |
| Asset Writedown & Restructuring Costs | - | - | 0 | 0.02 | 0 | 4.4 |
| Loss (Gain) From Sale of Investments | -0.84 | -0.84 | -2.05 | -1.96 | -1.11 | -0.3 |
| Provision & Write-off of Bad Debts | 0.2 | 0.2 | -0.02 | -0 | 0.02 | 0.11 |
| Other Operating Activities | -102.13 | -11.5 | 1.62 | 2.71 | 0.79 | 3.57 |
| Change in Accounts Receivable | 10.38 | 10.38 | -2.43 | -6.44 | -1.98 | -0.15 |
| Change in Inventory | 7.39 | 7.39 | -46.95 | -14.09 | -16.43 | 4.37 |
| Change in Accounts Payable | 3.71 | 3.71 | 43.2 | 27.73 | 3.32 | 6.89 |
| Change in Other Net Operating Assets | 1.42 | 1.42 | 0.9 | 2.68 | 0.07 | - |
| Operating Cash Flow | 242.04 | 252.52 | 165.32 | 138.65 | 87.14 | 61.91 |
| Operating Cash Flow Growth | 11.95% | 52.74% | 19.24% | 59.12% | 40.74% | - |
| Capital Expenditures | -47.81 | -13.65 | -40.65 | -152.03 | -58.2 | -18.49 |
| Sale of Property, Plant & Equipment | 0 | 0 | 0.14 | 0 | - | - |
| Investment in Securities | -1,451 | -1,301 | 48 | -14.43 | -17.52 | -24.13 |
| Other Investing Activities | 25.26 | 4.73 | 2.05 | 2.32 | 0.75 | 0.3 |
| Investing Cash Flow | -1,473 | -1,310 | 9.53 | -164.14 | -74.98 | -42.32 |
| Long-Term Debt Repaid | - | -2.34 | -2.92 | - | - | - |
| Net Debt Issued (Repaid) | -2.34 | -2.34 | -2.92 | - | - | - |
| Issuance of Common Stock | 995.48 | 995.48 | - | 225.66 | 17.99 | 55.27 |
| Common Dividends Paid | -68.78 | - | -3.44 | -30.95 | - | - |
| Other Financing Activities | -22.27 | -20.3 | -3.03 | -6.32 | -1.74 | -66.92 |
| Financing Cash Flow | 902.09 | 972.84 | -9.39 | 188.39 | 16.25 | -11.65 |
| Foreign Exchange Rate Adjustments | -0 | - | - | 0.24 | - | - |
| Net Cash Flow | -328.94 | -84.32 | 165.47 | 163.15 | 28.41 | 7.94 |
| Free Cash Flow | 194.22 | 238.87 | 124.67 | -13.38 | 28.93 | 43.42 |
| Free Cash Flow Growth | 3.18% | 91.60% | - | - | -33.37% | - |
| Free Cash Flow Margin | 15.58% | 23.13% | 14.56% | -2.30% | 6.53% | 15.58% |
| Free Cash Flow Per Share | 0.48 | 0.68 | 0.37 | -0.04 | 0.10 | 0.85 |
| Cash Income Tax Paid | 160.06 | 127.8 | 77.47 | 58.49 | 49.7 | 28.82 |
| Levered Free Cash Flow | -1,075 | 180.69 | 59.89 | -30.47 | -6.14 | - |
| Unlevered Free Cash Flow | -1,075 | 180.85 | 60.16 | -30.13 | -6.14 | - |
| Change in Net Working Capital | 1,239 | -19.47 | 30.69 | -27.07 | 22.78 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.